Merck KGaA. (11/7/22). "Press Release: Merck Announces Collaboration with Biotheus to Accelerate Drug Submission and Approval Process for Biopharmaceutical Industry in China". Shanghai.

	Region	China
	Organisation	Merck KGaA
	Group	Merck (DE) (Group)
	Organisation 2	Biotheus Inc. (CN)
	Product	Blazar® Rodent Panel
	Product 2	biopharmaceutical
	Person	Jaffré, Marc (Merck (DE) 202204 Managing Director of Life Science Business Sector in China)

> Merck to offer its first-to-market Blazar ® Rodent Panel for virus testing

> Reduces biosafety turnaround time by up to 80%

> Reduces animal testing through molecular-based technology

Merck, a leading science and technology company, today announced a collaboration with Biotheus, a China-based biotech company focused on developing treatments for cancer and autoimmune diseases. Utilizing Merck’s Blazar® Rodent Panel, Biotheus’ turn-around-time (TAT) of its cell line characterization reduced from around 60 days to 14 days.

“The pressure to shorten delivery times and reduce costs for biologics are driving an evolution in the biomanufacturing space,” said Marc Jaffré, Managing Director, Life Science business sector, Merck China. “Merck has a 75-year history of biosafety testing experience. With this state-of-the-art platform, Merck’s Blazar® Rodent Panel can support our biopharmaceutical clients in China to accelerate their scientific breakthroughs and produce safe, life-saving therapies faster.”

“The Blazar® Rodent Panel from Merck is one of the few technologies available on the market that will empower us in expediting approvals for IND and BLA in China and beyond,” said Xu Yingda, Vice President of Chemical Manufacturing and Control, Biotheus Inc. “We look forward to our continued collaboration with Merck, a global leader in biosafety testing and regulatory services, in the development of novel drugs to treat cancer and inflammatory disease, and expand our clinical trial activities worldwide.”

The award-winning Blazar® Rodent Panel from Merck can detect a much broader range of adventitious viruses compared to traditional Polymerase Chain Reaction methods as it targets conserved regions within virus families. The Blazar® Rodent Panel allows the biopharma industry to move away from using traditional animal experiments to detect rodent origin virus in the cell banks used in the production of the biologics. Introduced in Q3 2020, it also reduces the use of animals in accordance with the 4Rs principles – replacement, reduction, refinement and responsibility.

For more information, please contact Charlie Shen
+86 1350 165 7368
Email

All Merck news releases are distributed by email at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

About Merck

Merck, a leading science and technology company, operates across life science, healthcare and electronics. More than 60,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2021, Merck generated sales of €19.7 billion in 66 countries/regions.

Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.

Record changed: 2024-01-06